Key result
Nanocarrier tPA matches standard recanalization times using ~10% the dose while reducing systemic fibrinogen depletion.
Why the study?
A human-scale multiphysics model is needed to comparatively evaluate thrombolytic nanocarrier performance and dosing strategies under clinically relevant arterial conditions.
Does a platelet-targeted nanocarrier containing tPA improve recanalization time and reduce systemic fibrinogen depletion compared to free tPA in a human-scale arterial occlusion model?
Does a platelet-targeted nanocarrier containing tPA improve recanalization time and reduce systemic fibrinogen depletion compared to free tPA in a human-scale arterial occlusion model?
A computational multiphysics model suggests that a low-dose platelet-targeted tPA nanocarrier can achieve comparable recanalization to standard free tPA with less systemic fibrinogen depletion.
Answers are grounded in this paper and cite their sources.
Model enables in silico nanocarrier testing; leaves open clinical translation for arterial thrombolysis.
Objectives To develop a human-scale multiphysics model for comparative evaluation of thrombolytic nanocarrier performance and dosing strategies under clinically relevant arterial conditions. Methods We coupled a systemic pharmacokinetic-pharmacodynamic model with one-dimensional convection-diffusion-reaction transport in an occluded artery, incorporating platelet-triggered tissue plasminogen activator (tPA) release and formulation-specific effective binding to activated platelet sites. Twenty-two scenarios varied thrombus composition, nanocarrier formulation, and dosing regimen. Results PNC produced shorter predicted recanalization times than free tPA in platelet-rich thrombi when activated platelet density was sufficient to sustain triggered release. Matched-diffusivity comparisons indicated that diffusivity alone was insufficient to explain the formulation-dependent differences in intrathrombic retention and thrombolytic efficacy. These differences were associated with the combined formulation-specific binding, release, transport, and pharmacokinetic parameters represented in the model. A single low-dose PNC bolus containing 10% of the standard tPA dose achieved recanalization times comparable to those of standard-dose free tPA under the bolus-plus-infusion regimen while producing substantially less modeled systemic fibrinogen depletion. Conclusions The coupled model provides a quantitative framework for comparing thrombolytic nanocarrier behavior and dosing strategies under the specified human-scale arterial conditions and may help guide further preclinical evaluation of targeted thrombolytic nanocarriers.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied arterial occlusion. chitosan nanocarrier (PNC) thrombolysis vs. standard-dose free tPA was evaluated on recanalization time. A single low-dose chitosan nanocarrier bolus achieved recanalization times comparable to standard-dose free tPA with substantially less systemic fibrinogen depletion.
Synapse has enriched 10 related papers. Consider them for comparative context: